Exact Sciences stock closed at $36.47 Wednesday, up $3.82. The company’s shares have increased 449 percent during the past year.
The company’s completed test volume also grew year-over-year by 150 percent, according to the report.
More articles on supply chain:
Amgen sues FDA over drug exclusivity rights: 5 things to know
Appellate court: Fairvew Health’s medical device telemarketing does not violate robocall rules
Drug execs anticipate Trump’s drug pricing plans: 4 things to know
